Majewska Anna, Mlynarczyk-Bonikowska Beata, Malejczyk Magdalena, Mlynarczyk Grazyna, Majewski Slawomir
Department of Medical Microbiology, 5 Chalubinskiego Str., 02-004 Warsaw, Medical University of Warsaw, Poland.
Mini Rev Med Chem. 2015;15(2):93-103. doi: 10.2174/138955751502150305154459.
This is a second part of a review under a main title Antiviral medication in sexually transmitted diseases. In the part we published in Mini Rev Med Chem. 2013,13(13):1837-45, we have described mechanisms of action and mechanism of resistance to antiviral agents used in genital herpes and genital HPV infection. The Part II review focuses on therapeutic options in HIV infection. In 1987, 6 years after the recognition of AIDS, the FDA approved the first drug against HIV--zidovudine. Since then a lot of antiretroviral drugs are available. The most effective treatment for HIV is highly active antiretroviral therapy--a combination of several antiretroviral medicines that cause a reduction of HIV blood concentration and often results in substantial recovery of impaired immunologic function. At present, there are over 20 drugs licensed and used for the treatment of HIV/AIDS, and these drugs are divided into one of six classes. Investigational agents include GS-7340, the prodrug of tenofovir and BMS-663068--the first in a novel class of drugs that blocks the binding of the HIV gp120 to the CD4 receptor.
这是一篇题为《性传播疾病中的抗病毒药物》综述的第二部分。在我们发表于《Mini Rev Med Chem》2013年第13卷第13期第1837 - 45页的部分中,我们描述了用于治疗生殖器疱疹和生殖器HPV感染的抗病毒药物的作用机制和耐药机制。本综述的第二部分聚焦于HIV感染的治疗选择。1987年,继确认艾滋病6年后,美国食品药品监督管理局批准了第一种抗HIV药物——齐多夫定。从那时起,有了许多抗逆转录病毒药物。治疗HIV最有效的方法是高效抗逆转录病毒疗法——几种抗逆转录病毒药物联合使用,可降低血液中HIV浓度,并常常能使受损的免疫功能大幅恢复。目前,有20多种药物已获许可用于治疗HIV/AIDS,这些药物分为六类中的一类。研究中的药物包括替诺福韦的前体药物GS - 7340和BMS - 663068——这是新型药物中的第一种,可阻断HIV gp120与CD4受体的结合。
